A brief introduction to Cantargia

To the interview

CANFOUR clinical results, interview

To the interview (in Swedish)

Cantargia listed on Nasdaq Stockholm (Small Cap)

Read more

Two Nobel Prizes with utmost significance for Cantargia’s research

Read more

Latest press releases

(R) Cantargia makes a directed share issue of approximately SEK 106 million for increased investments in the clinical development of CAN04

(R) Cantargia publishes year end report for 2018

(R) Cantargia: first patient treated with antibody CAN04 in the phase IIa part of CANFOUR trial

* (R) = Regulatory press releases

Cantargia is a biotechnology company specialising in dual-action antibody-based cancer treatments. CAN04, the company's patented antibody treatment, has a dual-action and fights cancer by activating the immune system and by blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immunoncology.

Cantargia is since September 25, 2018 listed on Nasdaq Stockholm main market (Small Cap).

How CAN04 attacks a cancer tumour

Watch the animated video

Press releases

* (R) = Regulatory press releases

Show more press releases  >>